Compare CHGG & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHGG | BMEA |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.4M | 96.9M |
| IPO Year | 2013 | 2021 |
| Metric | CHGG | BMEA |
|---|---|---|
| Price | $0.89 | $1.03 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $1.42 | ★ $8.71 |
| AVG Volume (30 Days) | ★ 3.0M | 1.2M |
| Earning Date | 11-10-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $447,733,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.44 | $0.87 |
| 52 Week High | $2.73 | $7.46 |
| Indicator | CHGG | BMEA |
|---|---|---|
| Relative Strength Index (RSI) | 39.00 | 34.94 |
| Support Level | $0.87 | $0.87 |
| Resistance Level | $1.01 | $1.12 |
| Average True Range (ATR) | 0.11 | 0.09 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 4.93 | 27.93 |
Chegg Inc is an American educational services company. The Chegg platform provides products and services to support learners with their academic course materials, as well as their career and personal skills development. The company's service and product offerings fall into two categories: Subscription Services, which encompasses Chegg Study Pack, Chegg Study, Chegg Writing, Chegg Math, and Busuu offerings that can be accessed internationally through the company's websites and on mobile devices, and Skills and Other, which encompasses skills, advertising services, print textbooks, and eTextbooks offerings.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.